D. Moore

D. Moore, B. Mattar, Bassem M. Chehab, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study

D. Moore, W. Samlowski, J. Medina, 1998, Investigational New Drugs.

Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma.

B. Levin, D. Moore, R. Winn, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.

J. Ajani, D. Moore, R. Winn, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)

J. Buckner, D. Moore, E. Galanis, 2007 .

Phase I trial of Taxotere: five-day schedule.

D. Moore, R. Pazdur, R. Newman, 1992, Journal of the National Cancer Institute.

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia

P. Novotny, J. Sloan, D. Moore, 2015, American journal of hematology.

A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA.

J. Sloan, D. Moore, C. Loprinzi, 2011, The journal of supportive oncology.

Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial

R. Fisher, M. Leblanc, D. Moore, 2000, Anti-cancer drugs.

Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience.

D. Moore, S. Dakhil, K. Choucair, 2022, Clinical Breast Cancer.

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus

D. Moore, S. Hurvitz, Xiaoyan Wang, 2020, Therapeutic advances in medical oncology.

A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.

Minetta C. Liu, G. Sledge, D. Moore, 2016 .

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

E. Perez, J. Jett, S. Mandrekar, 2008, Lung cancer.

Overview of prognostic factors in non-Hodgkin's lymphoma.

D. Moore, F. Cabanillas, F. Cabanillas, 1998, Oncology.

Modulation of fluorouracil with recombinant alfa interferon: M. D. Anderson Clinical trial.

D. Moore, R. Pazdur, B. Bready, 1992, Seminars in oncology.

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997

M. Grever, J. Byrd, J. Gribben, 2015, Leukemia & lymphoma.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Caterina Giannini, Jan C Buckner, B. Scheithauer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non–Small‐cell Lung Cancer: SWOG S0635 and S0636 Trials

F. Hirsch, K. Kelly, A. Wozniak, 2018, Clinical lung cancer.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Jason McCoy, Robert A Chapman, Bart Barlogie, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benign metastasizing leiomyomatosis: case report and review.

D. Moore, C. Garrett, K. Goyle, 2003, American journal of clinical oncology.

Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial.

E. Shaw, S. Rapp, A. Peiffer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

D. Moore, N. Foster, S. Alberts, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.

J. Crowley, D. Moore, R. Livingston, 1999, The cancer journal from Scientific American.

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma

D. Moore, S. Arbuck, R. Winn, 1998, Investigational New Drugs.

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.

D. Moore, S. Arbuck, R. Winn, 1998, Investigational new drugs.

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

A. Oberg, L. Hartmann, D. Moore, 2011, Gynecologic oncology.

A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results

J. Crowley, B. Barlogie, D. Moore, 2008 .

The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study.

D. Moore, P. Flynn, J. Atkins, 2003, Journal of pain and symptom management.

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

R. Beart, N. Wolmark, D. Moore, 2015, Journal of the National Cancer Institute.

Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

J. Crowley, D. Moore, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

N. Petrelli, R. Beart, N. Wolmark, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

D. Moore, C. Reeder, S. Geyer, 2008, Leukemia & lymphoma.

Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma

D. Moore, S. Ansell, K. Rowland, 2008, Cancer.

What constitutes a "cure" in lymphoma?

D. Moore, F. Cabanillas, 1993, Leukemia & lymphoma.

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

D. Moore, J. Schiller, A. Dowlati, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001

K. Stelzer, D. Moore, A. Sloan, 2015, International Journal of Clinical Oncology.

Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.

D. Moore, T. Witzig, M. Maurer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small Lymphocytic Lymphoma Presenting with Hypopituitarism.

D. Moore, C. Pinnix, F. Samaniego, 2016, The American journal of medicine.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

M. Prados, C. Miller, J. Sarkaria, 2018, Neuro-oncology.

Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).

D. Moore, S. Vadhan-Raj, 1995, The American journal of medicine.

Waldenström macroglobulinemia presenting as a renal or perirenal mass: clinical and radiographic features.

M. Dimopoulos, D. Moore, L. Moulopoulos, 1995, Leukemia & lymphoma.

Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, British journal of haematology.

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant

D. Moore, Bharat Malhotra, K. Kallail, 2015, Case reports in transplantation.

Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.

Terry L. Smith, R. Millikan, D. Moore, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.

J. Jett, B. Bot, S. Mandrekar, 2007, International journal of radiation oncology, biology, physics.

A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial

J. Sloan, D. Moore, C. Loprinzi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of gemcitabine in advanced colorectal adenocarcinoma

D. Moore, R. Pazdur, J. Abbruzzese, 1992, Investigational New Drugs.

The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5).

J. Sloan, D. Moore, C. Loprinzi, 2011, The journal of supportive oncology.

Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105.

E. Shaw, S. Rapp, A. Peiffer, 2018, Neuro-oncology practice.

Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma.

S. Lippman, D. Moore, R. Pazdur, 1995, American journal of clinical oncology.

The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study

J. Crowley, B. Barlogie, D. Moore, 2002, Investigational New Drugs.

Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer

E. Saad, D. Moore, R. Pazdur, 2002, American journal of clinical oncology.

Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Preliminary Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes: North Central Cancer Treatment Group (N0044)

H. McLeod, D. Moore, N. Foster, 2007, American journal of clinical oncology.

Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men

E. Messing, C. Heckler, D. Moore, 2011, Supportive Care in Cancer.

Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas.

D. Moore, R. Pazdur, B. Bready, 1991, Seminars in oncology.

A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma

D. Moore, T. Witzig, M. Maurer, 2008 .

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

M. Grever, J. Byrd, J. Gribben, 2010 .

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

D. Moore, N. Foster, K. Rowland, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma.

D. Moore, N. Foster, S. Alberts, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of intravenous melphalan in advanced colorectal carcinoma

D. Moore, R. Pazdur, J. Abbruzzese, 2004, Investigational New Drugs.

Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors.

E. Shaw, S. Rapp, A. Peiffer, 2013 .

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

J. Friedberg, L. Rimsza, R. Fisher, 2014 .